Table 3.
Treatment outcomes and adverse reactions in the two groups.
| Observation indicators | PAE (n=150) | VP (n=135) | Z/χ2 | P-value |
|---|---|---|---|---|
| Hemostatic Efficacy | 52.388 | <0.001 | ||
| Significant Improvement | 121 (80.7%) | 31 (23.0%) | ||
| Moderate Improvement | 20 (13.3%) | 47 (34.8%) | ||
| No Improvement | 9 (6.0%) | 57 (42.2%) | ||
| Total Effective Cases | 141 (94.0%) | 78 (57.8%) | ||
| Hematological parameters | ||||
| HB change value (g/L) | 1.0 (-5.0-9.3) | -4.0 (-10.0-2.0)* | -4.692 | <0.001 |
| RBC change value (x10^12/L) | 0.0 (-0.2-0.3) | -0.2 (-0.4-0.0)* | -4.599 | <0.001 |
| HCT change value (%) | 0.3 (-1.7-2.3) | -1.4 (-3.5-0.6)* | -4.460 | <0.001 |
| PLT change value (x10^9/L) | -0.5 (-25.5-26.0) | -5.0 (-40.0-24.0) | -1.309 | 0.191 |
| Adverse Reactions | ||||
| Local infection | 4 (2.7%) | 17 (12.6%) | 10.256 | 0.001 |
| Pelvic persistent pain | 46 (30.7%) | 63 (46.7%) | 7.701 | 0.006 |
| Gastrointestinal reactions | 10 (6.7%) | 8 (5.9%) | 0.066 | 0.797 |
| Fever | 23 (15.3%) | 9 (6.7%) | 5.354 | 0.021 |
| Recurrence of bleeding | 5 (3.3%) | 14 (10.4%) | 5.655 | 0.017 |
*indicated statistically significant differences compared with pre-treatment levels, P<0.05. Significant improvement = bleeding cessation ≤ 24 h after treatment; Moderate improvement = bleeding cessation ≤ 3 days or minimal bleeding ≤ 7 days; No improvement = bleeding persisting > 7 days. Total hemostatic efficacy rate = (Significant improvement + Moderate improvement) /total cases × 100%; “Pelvic persistent pain” was defined as persistent pain lasting more than 3 days after treatment.